The federal agency has stamped a full approval — following last year’s conditional OK — on Merck’s mega-blockbuster Keytruda for frontline use in a chemo combo for fighting non-squamous non-small cell lung cancer.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,